Novo Nordisk Seeks Growth Beyond Flagship Drugs with New Obesity Pill Trial

Novo Nordisk starts Phase 1 trial for oral obesity drug LX9851, a strategic move to diversify beyond GLP-1 drugs like Wegovy amid pricing pressure and stock decline.

Facing significant pricing pressure on its blockbuster medications Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk is advancing a novel drug candidate with a different mechanism of action. The initiation of a Phase 1 clinical study for an oral weight-loss pill, LX9851, underscores a strategic pivot to reduce the company's reliance on its current GLP-1 class of treatments.

The candidate, sourced from a licensing agreement with Lexicon Pharmaceuticals, represents a distinct scientific approach. Unlike the injectable incretin-based therapies, this oral compound works by selectively inhibiting an enzyme involved in regulating fat storage and energy balance. The commencement of the study triggers an initial $10 million payment to Lexicon, with the total agreement potentially worth up to $1 billion in long-term milestone payments.

Strategic Diversification Amid Market Pressure

This pipeline development arrives at a crucial juncture for Novo Nordisk. The company's management recently faced shareholders at its Annual General Meeting against a backdrop of a challenging year for its stock. Shares have declined more than 54% over a twelve-month period, recently trading at €31.68—hovering just above a 52-week low.

The downturn is largely attributed to revised prospects for the core business. New CEO Mike Doustdar has warned of a potential sales decline this year, driven in part by a new pricing agreement with the U.S. government. Through the direct distribution channel "TrumpRx," the company must now offer Wegovy and Ozempic at significantly lower prices, putting considerable pressure on profit margins.

To support shareholder value during this phase, the firm is executing a consistent capital return program. A share buyback initiative totaling 15 billion Danish kroner is underway, with approximately 7.8 million shares already repurchased by the end of last week.

Focus on Combination Therapy and Patient Retention

Preclinical data provides the rationale for Novo Nordisk's substantial financial commitment to LX9851. Early tests indicate the new drug could potentially enhance weight loss when used in combination with established semaglutide-based treatments. Furthermore, research suggests a secondary benefit: LX9851 may help mitigate the rebound weight gain, or "yo-yo effect," often observed after discontinuing current injectable therapies.

According to research head Jacob Sten Petersen, this approach represents a key strategic addition to better address diverse patient needs in obesity and diabetes care moving forward. The expansion of the clinical pipeline with LX9851 is viewed as an essential operational move to build new revenue streams and counter long-term margin pressure within the GLP-1 portfolio.